Junshi Biosciences' stock surged 5.11% during intraday trading on Monday, extending its recent positive momentum in the market.

The movement appears driven by multiple catalysts, including the disclosure of key clinical data at the ongoing American Association for Cancer Research (AACR) annual meeting. The company presented data for two flagship pipeline candidates: JS207 (a PD-1/VEGF bispecific antibody) and JS212 (an EGFR/HER3 ADC), with plans to advance both toward pivotal registration trials within the year.

Additional support came from Pacific Securities raising its target price for Junshi Biosciences to RMB 53.12 with a "Buy" rating. The company also reported full-year revenue growth of 28.23%, with core product Toripalimab achieving over 40% sales growth, and the expiration without execution of its third-largest shareholder's share reduction plan, removing a potential overhang.